Downloads
AudioCure is pleased to provide a range of easy to print, downloads including factsheets about the company, the ear and hearing disorders and our press releases.
PDF File, 124 KB
AudioCure Pharma’s AC102 receives FDA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL).
PDF File, 140 KB
AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102.
Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear. The trial is conducted at Radboud University Medical Center (Radboudumc) in The Netherlands.
PDF File, 146 KB
AudioCure Pharma GmbH, ein pharmazeutisches Forschungsunternehmen mit Sitz in Berlin, gibt heute den Start der klinischen Prüfung der Phase I mit dem neuartigen Wirkstoff AC102 bekannt.
Die Studie wird mit gesunden Probanden durchgeführt, um die Sicherheit und Verträglichkeit von AC102 nach Injektion in das Mittelohr zu prüfen. Studienzentrum ist das Medical Center der Radboud Universität (Radboudumc), in den Niederlanden.
PDF File, 136 KB
AudioCure Pharma’s AC102 receives EMA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)
Press Release: The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL).
PDF File, 102 KB
AC102 von AudioCure Pharma erhält Orphan Drug-Status der EMA für die Behandlung des plötzlichen, sensorineuralen Hörverlusts (SSNHL)
Pressemitteilung: Das Komitee für seltene Erkrankungen der Europäischen Arzneimittel-Agentur (EMA) hat AC102 den Orphan Drug-Status mit der Begründung verliehen, dass der Leitwirkstoff von AudioCure erheblichen Nutzen für Patienten haben kann, die unter plötzlichem, sensorineuralem Hörverlust (SSNHL) leiden. SSNHL ist eine seltene Krankheit, mit hohem Leidensdruck.
PDF File, 275 KB
Our Technology
On overview of AudioCure’s lead compound and our specialized formulation and application
PDF File, 247 KB
Inner Ear Disorders
An overview of the anatomy of the ear and how damage can lead to hearing loss
PDF File, 232 KB
Financing Round 29 Nov 2016
Press Release: AudioCure Pharma GmbH secures funding of about EUR 9 million for the further development of their lead candidate, AC102, in hearing loss
PDF File, 229 KB
Finanzierungsrunde 29 Nov 2016
Pressemitteilung: AudioCure Pharma GmbH schließt erfolgreich eine Finanzierungsrunde über rund 9 Million Euro ab
PDF File, 80 KB
Notes to the Editor 2016
About AudioCure and its investors: MED-EL and High-Tech-Gründerfonds
PDF File, 218 KB
Financing Round 29 May 2012
Press Release: AudioCure successfully completes the initial financing round with High-Tech-Gründerfonds (HTGF)
PDF File, 221 KB
Finanzierungsrunde 29 Mai 2012
Pressemitteilung: AudioCure schließt die erste Finanzierungsrunde mit High-Tech-Gründerfonds (HTGF) ab